Fujifilm Extends Regional Presence Through Danish Acquisition
Fujifilm has bought Biogen ApS’ Copenhagen facility for US$890 million.
Fujifilm Diosynth Biotechnologies has acquired Biogen Manufacturing ApS near Copenhagen, Denmark for US$890 million in cash, according to a company press release that was issued on Aug. 1, 2019. This is the fourth facility that the contract development and manufacturing organization (CDMO) has acquired since it was established in 2011.
The new site has nearly 800 employees and includes a large-scale production facility with six 15,000-L bioreactors; an assembly, labeling and packaging facility; and quality control laboratories and warehouses.
“We will seek to continue the further advancement of the pharmaceutical industry by serving our range of diverse customers’ needs through combining resources of the Biogen (Denmark) Manufacturing ApS and Fujifilm,” said Takatoshi Ishikawa, executive vice president and general manager of Fujifilm Corporation’s Bio CDMO division, in the press release.
Source: Fujifilm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
